ZJJF(SH:600668) Zheng Quan Zhi Xing·2025-08-29 10:24Core Viewpoint - The company reported a decline in its main business revenue and costs for the first half of 2025 compared to the same period in 2024, indicating challenges in the pharmaceutical manufacturing sector and other related industries [1][2]. Summary by Category Industry Performance - The overall main business revenue for the company in the first half of 2025 was 1,242.61 million RMB, a decrease of 3.38% from 1,286.13 million RMB in the same period of 2024 [1]. - The main business cost for the same period was 955.96 million RMB, down 6.48% from 1,022.20 million RMB in 2024 [1]. - The gross profit margin decreased from 20.52% in 2024 to 23.07% in 2025 [1]. Product Performance - Cement revenue was 503.17 million RMB, a decrease of 2.29% from 514.96 million RMB in 2024, with a gross profit margin of 20.60%, down from 16.44% [2]. - Pharmaceutical products saw a revenue decrease of 1.83% [4]. - Health products revenue increased by 5.44% to 81.73 million RMB, with a gross profit margin of 24.55%, up from 26.38% [4]. - Other products experienced a revenue decline of 10.33% [4]. Regional Performance - Revenue from the Zhejiang region was 453.56 million RMB, down 9.79% from 502.80 million RMB in 2024 [4]. - Hubei region revenue increased by 4.99% to 339.99 million RMB [4]. - Tianjin region saw an 8.75% increase in revenue to 71.58 million RMB [4]. - Other regions, such as Yunnan and Guizhou, experienced revenue declines of 6.12% and 10.28%, respectively [4].